Proactive Investors - Run By Investors For Investors

Sareum submits cancer trial application

The application means a £200,000 success milestone payment from Cancer Research Technology to Sareum.
Sareum submits cancer trial application
Two clinical trials in cancer patients are planned.

Drug developer Sareum (LON:SAR) has submitted its application for two Phase I clinical trials of CHK1 inhibitor CCT245737  to the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The application means a £200,000 success milestone payment from Cancer Research Technology to Sareum. 

Two clinical trials in cancer patients are planned. One will use CCT245737 as a single anti-cancer agent and the other in combination with standard-of-care chemotherapy.

Once approval is obtained, these trials will be funded in collaboration with co-development partner, the CRT Pioneer Fund.

Sareum has put up £797,500 of development funding so far.

Tim Mitchell, chief executive, said it was a further significant step towards the planned clinical trials with cancer patients.

Checkpoint Kinase 1 (CHK1)  helps control the way many cancer cells respond to DNA damage, which may be a consequence of the cancer itself, or intentionally caused by chemotherapy or radiotherapy. Inhibition of CHK1 affects the ability of the cell to repair this damage. 

Why Invest In Sareum Holdings Plc? Read More Here

Register here to be notified of future SAR Company articles
View full SAR profile

Sareum Holdings Plc Timeline

May 17 2016
March 24 2016

Related Articles

Cancer cell graphic
September 27 2016
Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.
Magnified view of cancer cells
July 28 2016
ANGLE's Parsortix blood screening system could replace the traditional biopsy in the diagnosis of breast cancer. Proactive takes a look at how it works and the potential it holds to change the way cancer is diagnosed.
Blood test
September 27 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.